Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/22/2022 | $34.00 → $24.00 | Outperform | Wedbush |
| 2/11/2022 | $19.00 | Buy | Goldman Sachs |
Wedbush reiterated coverage of Codiak BioSciences with a rating of Outperform and set a new price target of $24.00 from $34.00 previously
Goldman Sachs initiated coverage of Codiak BioSciences with a rating of Buy and set a new price target of $19.00
CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that the Company has voluntarily filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and will seek to pursue a sale process for its assets which is intended to maximize the value of the Company. The Company began a marketing process ahead of the Chapter 11 filing to determine the level of market interest and is in ongoing discussions with several parties. The Company expects
CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that management will be participating in the 5th Annual Evercore ISI HealthCONx Conference, a virtual conference. Codiak's Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a fireside chat on Wednesday, November 30 at 8:00 am ET and the Company will also be hosting one-on-one meetings at the conference. A live webcast of the fireside chat will be available on the Investors & Media section of the Codiak website at www.codiakbio.com. A
– exoASO-STAT6 demonstrated durable pharmacokinetic/pharmacodynamic profile in preclinical models; biomarkers with clinical translational potential identified, providing a rationale for selecting cancer subtypes for treatment with exoASO-STAT6 – – Systemically administered exoASO-C/EBPβ demonstrated extra-hepatic delivery and potent systemic anti-tumor activity across multiple myeloid-derived suppressor cell (MDSC) rich tumor models – – A Phase 1 clinical trial of exoASO-STAT6 in patients with advanced hepatocellular carcinoma (HCC), is ongoing; initial data expected in the first half of 2023 – CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a
– Codiak's engineered exosome candidates demonstrate potential for best-in-class profile, with tumor retention and delivery to the cells of interest allowing for increased therapeutic window – – exoSTING and exoIL-12 demonstrated favorable safety and tolerability profile at repeat doses tested and antitumor activity was observed in both injected and uninjected/distal lesions – – Codiak has identified recommended Phase 2 dose for each program and plans to initiate Phase 2 studies for both candidates in the first quarter of 2023 – – Codiak to host conference call and webcast today at 8:00 am ET – CAMBRIDGE, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK),
– Reported positive initial data from exoSTING™ clinical trial; on track to provide data from all dose escalation cohorts in late 1H 2022 – – Investigational New Drug (IND) application cleared for exoASO™-STAT6, with clinical trial initiation expected 1H 2022 – – Initial safety, PK/PD and efficacy data for exoIL-12™ in CTCL patients anticipated late 1H 2022 – – Progressed preclinical pan-beta coronavirus vaccine program – CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today reported fourth quarte
– exoSTING resulted in localized STING pathway activation and dose-dependent immune activation – – Intratumoral administration of exoSTING was well tolerated and demonstrated tumor retention, no systemic exposure to STING agonist, and in a subset of patients, tumor shrinkage in injected and distal non-injected lesions – – Data on objective response rate and recommended Phase 2 dose selection for expansion anticipated 1H 2022 – – Codiak to host conference call and webcast today at 8:00 am ET – CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therap
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the appointment of David Mauro, M.D., Ph.D., a veteran oncology and immunotherapy drug developer, as Chief Medical Officer. Dr. Mauro will provide leadership and expertise for Codiak's pipeline of clinical development programs through early-stage trials to global regulatory submissions and joins the company's Executive Leadership Team reporting to Douglas E. Williams, Ph.D., President and CEO. "We have been fortunate to work with David since late last year
Werner Brings More Than Two Decades of Pharmaceutical Leadership to the Role CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced it has strengthened its executive leadership team with the appointment of Michelle C. Werner to the dual role of CEO-Partner of Flagship Pioneering and Chief Executive Officer of Alltrna. Werner brings to Flagship significant experience as a global pharmaceutical leader spanning both Commercial and Research and Development (R&D) responsibilities. Werner most recently served as Wo
CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of research programs. Prior to ORDR, she worked at the U.S. Food and Drug Administration (FDA) Center for
25-NSE - Codiak BioSciences, Inc. (0001659352) (Subject)
NT 10-K - Codiak BioSciences, Inc. (0001659352) (Filer)
8-K - Codiak BioSciences, Inc. (0001659352) (Filer)
4 - Codiak BioSciences, Inc. (0001659352) (Issuer)
4 - Codiak BioSciences, Inc. (0001659352) (Issuer)
4 - Codiak BioSciences, Inc. (0001659352) (Issuer)
SC 13G/A - Codiak BioSciences, Inc. (0001659352) (Subject)
SC 13G/A - Codiak BioSciences, Inc. (0001659352) (Subject)
SC 13G/A - Codiak BioSciences, Inc. (0001659352) (Subject)